Literature DB >> 23977538

Mesothelin-targeted immunotherapies for malignant pleural mesothelioma.

Jonathan Villena-Vargas1, Prasad S Adusumilli.   

Abstract

Entities:  

Year:  2012        PMID： 23977538      PMCID： PMC3741795          DOI： 10.3978/j.issn.2225-319X.2012.10.03

Source DB:  PubMed          Journal:  Ann Cardiothorac Surg        ISSN： 2225-319X


× No keyword cloud information.
  38 in total

1.  A new pyrimidine-specific reporter gene: a mutated human deoxycytidine kinase suitable for PET during treatment with acycloguanosine-based cytotoxic drugs.

Authors:  Yury Likar; Juan Zurita; Konstantin Dobrenkov; Larissa Shenker; Shangde Cai; Anton Neschadim; Jeffrey A Medin; Michel Sadelain; Hedvig Hricak; Vladimir Ponomarev
Journal:  J Nucl Med       Date:  2010-09       Impact factor: 10.057

2.  Pre-clinical mouse models of primary and metastatic pleural cancers of the lung and breast and the use of bioluminescent imaging to monitor pleural tumor burden.

Authors:  Elliot L Servais; Christos Colovos; Stefan S Kachala; Prasad S Adusumilli
Journal:  Curr Protoc Pharmacol       Date:  2011-09

3.  Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning.

Authors:  Hollie J Pegram; James C Lee; Erik G Hayman; Gavin H Imperato; Thomas F Tedder; Michel Sadelain; Renier J Brentjens
Journal:  Blood       Date:  2012-02-21       Impact factor: 22.113

Review 4.  Mesothelin-targeted agents in clinical trials and in preclinical development.

Authors:  Ronan J Kelly; Elad Sharon; Ira Pastan; Raffit Hassan
Journal:  Mol Cancer Ther       Date:  2012-02-17       Impact factor: 6.261

5.  Mesothelin-family proteins and diagnosis of mesothelioma.

Authors:  Bruce W S Robinson; Jenette Creaney; Richard Lake; Anna Nowak; A William Musk; Nick de Klerk; Pernilla Winzell; Karl Erik Hellstrom; Ingegerd Hellstrom
Journal:  Lancet       Date:  2003-11-15       Impact factor: 79.321

Review 6.  The promise and potential pitfalls of chimeric antigen receptors.

Authors:  Michel Sadelain; Renier Brentjens; Isabelle Rivière
Journal:  Curr Opin Immunol       Date:  2009-03-25       Impact factor: 7.486

7.  Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers.

Authors:  K Chang; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-09       Impact factor: 11.205

8.  Listeria-based cancer vaccines that segregate immunogenicity from toxicity.

Authors:  Dirk G Brockstedt; Martin A Giedlin; Meredith L Leong; Keith S Bahjat; Yi Gao; William Luckett; Weiqun Liu; David N Cook; Daniel A Portnoy; Thomas W Dubensky
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-13       Impact factor: 11.205

9.  Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma.

Authors:  Paul Wheatley-Price; Boming Yang; Demetris Patsios; Devalben Patel; Clement Ma; Wei Xu; Natasha Leighl; Ronald Feld; B C John Cho; Brenda O'Sullivan; Heidi Roberts; Ming Sound Tsao; Martin Tammemagi; Masaki Anraku; Zhuo Chen; Marc de Perrot; Geoffrey Liu
Journal:  J Clin Oncol       Date:  2010-05-24       Impact factor: 44.544

10.  HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia.

Authors:  C Bonini; G Ferrari; S Verzeletti; P Servida; E Zappone; L Ruggieri; M Ponzoni; S Rossini; F Mavilio; C Traversari; C Bordignon
Journal:  Science       Date:  1997-06-13       Impact factor: 47.728
View more
  9 in total

Review 1.  Immunotherapy for non-small cell lung cancer: current concepts and clinical trials.

Authors:  Marissa Mayor; Neng Yang; Daniel Sterman; David R Jones; Prasad S Adusumilli
Journal:  Eur J Cardiothorac Surg       Date:  2015-10-29       Impact factor: 4.191

2.  Surgical cytoreduction restores the antitumor efficacy of a Listeria monocytogenes vaccine in malignant pleural mesothelioma.

Authors:  Gregory T Kennedy; Brendan F Judy; Pratik Bhojnagarwala; Edmund K Moon; Zvi G Fridlender; Steven M Albelda; Sunil Singhal
Journal:  Immunol Lett       Date:  2015-05-18       Impact factor: 3.685

Review 3.  CAR T-cell therapy for lung cancer and malignant pleural mesothelioma.

Authors:  Masha Zeltsman; Jordan Dozier; Erin McGee; Daniel Ngai; Prasad S Adusumilli
Journal:  Transl Res       Date:  2017-04-26       Impact factor: 7.012

4.  Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity.

Authors:  Prasad S Adusumilli; Leonid Cherkassky; Jonathan Villena-Vargas; Christos Colovos; Elliot Servais; Jason Plotkin; David R Jones; Michel Sadelain
Journal:  Sci Transl Med       Date:  2014-11-05       Impact factor: 17.956

Review 5.  Improving theranostics in pancreatic cancer.

Authors:  Jeremy King; Michael Bouvet; Gagandeep Singh; John Williams
Journal:  J Surg Oncol       Date:  2017-05-17       Impact factor: 3.454

Review 6.  Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors.

Authors:  Aurore Morello; Michel Sadelain; Prasad S Adusumilli
Journal:  Cancer Discov       Date:  2015-10-26       Impact factor: 39.397

7.  The Emerging World of TCR-T Cell Trials Against Cancer: A Systematic Review.

Authors:  Jianxiang Zhang; Lingyu Wang
Journal:  Technol Cancer Res Treat       Date:  2019-01-01

Review 8.  Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer.

Authors:  Prameela Kandra; Rajender Nandigama; Bastian Eul; Magdalena Huber; Sebastian Kobold; Werner Seeger; Friedrich Grimminger; Rajkumar Savai
Journal:  Front Immunol       Date:  2022-06-02       Impact factor: 8.786

9.  Development of improved therapeutic mesothelin-based vaccines for pancreatic cancer.

Authors:  Michael White; Andrew Freistaedter; Gwendolyn J B Jones; Emmanuel Zervos; Rachel L Roper
Journal:  PLoS One       Date:  2018-02-23       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.